Vistagen Reports FY26 Results, Phase 3 Social Anxiety Data Expected This Month
Summary
Vistagen Therapeutics reported its fiscal year 2026 financial results and provided a corporate update, highlighting significant progress in its clinical pipeline. The company completed the randomized portion of its PALISADE-4 Phase 3 trial for social anxiety disorder, with topline results anticipated later this month. Additionally, Vistagen completed the randomized portion of its fasedienol Phase 2 repeat dose study, with results expected in Q3 2026, and received FDA clearance to proceed with Phase 2 development for refisolone. This comprehensive update, which includes several previously announced clinical milestones, is critical for the small biotech, especially given its prior disclosure of going concern doubts. The upcoming PALISADE-4 data readout this month is a major near-term catalyst.
At the time of this announcement, VTGN was trading at $0.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.7M. The 52-week trading range was $0.43 to $5.14. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.